Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA 19107.
Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA 19107
J Immunol. 2019 Feb 15;202(4):1301-1310. doi: 10.4049/jimmunol.1801206. Epub 2019 Jan 14.
Characterizing self-tolerance mechanisms and their failure is critical to understand immune homeostasis, cancer immunity, and autoimmunity. However, examination of self-tolerance mechanisms has relied primarily on transgenic mice expressing TCRs targeting well-characterized, but nonphysiologic, model Ags, such as OVA and hemagglutinin. Identifying TCRs directed against bona fide self-antigens is made difficult by the extraordinary diversity of TCRs and the low prevalence of Ag-specific clones (<10-100 naive cells per organism), limiting dissection of tolerance mechanisms restricting immunity to self-proteins. In this study, we isolated and characterized TCRs recognizing the intestinal epithelial cell receptor and colorectal cancer Ag GUCY2C to establish a model to study self-antigen-specific tolerance mechanisms. GUCY2C-specific CD4 effector T cells were isolated from immunized, nontolerant mice. Next-generation sequencing identified GUCY2C-specific TCRs, which were engineered into CD4 T cells in vitro to confirm TCR recognition of GUCY2C. Further, the generation of "retrogenic" mice by reconstitution with TCR-transduced hematopoietic stem cells resulted in normal CD4 T cell development, responsiveness to immunization, and GUCY2C-induced tolerance in recipient mice, recapitulating observations in conventional models. This retrogenic model can be employed to define self-tolerance mechanisms restricting T and B cell responses to GUCY2C to optimize colorectal cancer immunotherapy without autoimmunity.
表征自身耐受机制及其失败对于理解免疫稳态、癌症免疫和自身免疫至关重要。然而,自身耐受机制的研究主要依赖于表达针对经过充分研究但非生理的模型抗原(如 OVA 和红细胞凝集素)的 TCR 的转基因小鼠。由于 TCR 的多样性极大,以及抗原特异性克隆的低流行率(每个机体中<10-100 个幼稚细胞),使得鉴定针对真正自身抗原的 TCR 变得困难,限制了对限制自身蛋白免疫的耐受机制的剖析。在这项研究中,我们分离和鉴定了识别肠上皮细胞受体和结直肠癌细胞抗原 GUCY2C 的 TCR,以建立研究自身抗原特异性耐受机制的模型。从免疫、非耐受的小鼠中分离出 GUCY2C 特异性 CD4 效应 T 细胞。下一代测序鉴定了 GUCY2C 特异性 TCR,将其在体外工程化到 CD4 T 细胞中以确认 TCR 对 GUCY2C 的识别。此外,通过用转导了 TCR 的造血干细胞再构成“基因改造”小鼠,导致受者小鼠中出现正常的 CD4 T 细胞发育、对免疫的反应性和 GUCY2C 诱导的耐受,再现了在常规模型中的观察结果。这种基因改造模型可用于定义限制 GUCY2C 引起的 T 和 B 细胞反应的自身耐受机制,从而在不引发自身免疫的情况下优化结直肠癌免疫治疗。